Stock QURE UNIQURE N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Company uniQure N.V.

Equities

QURE

NL0010696654

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 01:30:00 27/04/2024 am IST 		5-day change 1st Jan Change
4.53 USD -0.22% Intraday chart for uniQure N.V. -3.00% -33.09%
12/04 Uniqure N.V. Announces Paula Soteropoulos Will Not Stand for Re-Election as Non-Executive Director CI
02/04 UBS Lowers UniQure's Price Target to $27 From $38, Maintains Buy Rating MT

Business Summary

Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

Number of employees: 480

Sales per Business

USD in Million2022Weight2023Weight Delta
Gene Therapies
100.0 %
106 100.0 % 16 100.0 % -85.12%

Managers

Managers TitleAgeSince
Matt Kapusta CEO
 Chief Executive Officer 51 01/15/01
Christian Klemt DFI
 Director of Finance/CFO 51 01/15/01
Pierre Caloz COO
 Chief Operating Officer 52 17/21/17
Richard Porter CTO
 Chief Tech/Sci/R&D Officer - 01/21/01
Jeannette Potts CMP
 Compliance Officer 62 -
Walid Abi-Saab CTO
 Chief Tech/Sci/R&D Officer 59 26/23/26
Robert Gut BRD
 Director/Board Member 59 13/18/13
Maria E. Cantor IRO
 Public Communications Contact 56 27/16/27
Erin Boyer HRO
 Human Resources Officer - 01/22/01

Members of the board

Members of the board TitleAgeSince
Leonard Post BRD
 Director/Board Member 72 17/20/17
Jack Kaye BRD
 Director/Board Member 80 15/16/15
Jeremy Springhorn BRD
 Director/Board Member 61 14/17/14
Matt Kapusta CEO
 Chief Executive Officer 51 01/15/01
David Meek CHM
 Chairman 59 13/18/13
Madhavan Balachandran BRD
 Director/Board Member 73 14/17/14
Paula Soteropoulos BRD
 Director/Board Member 56 01/13/01
Robert Gut BRD
 Director/Board Member 59 13/18/13
Jacques Suzanne BRD
 Director/Board Member 53 21/21/21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 47,838,275 43,109,998 ( 90.12 %) 0 90.12 %

Shareholders

NameEquities%Valuation
Vestal Point Capital LP
8.205 %
3,925,000 8.205 % 20 M $
STATE STREET CORPORATION
7.272 %
3,478,872 7.272 % 18 M $
Nantahala Capital Management LLC
6.183 %
2,958,027 6.183 % 15 M $
BRISTOL-MYERS SQUIBB COMPANY
4.992 %
2,388,108 4.992 % 12 M $
Morgan Stanley Capital Services LLC
3.679 %
1,759,818 3.679 % 9 M $
683 Capital Management LLC
3.539 %
1,693,000 3.539 % 9 M $
BlackRock Advisors LLC
3.346 %
1,600,844 3.346 % 8 M $
OrbiMed Advisors Private Equity
2.818 %
1,347,900 2.818 % 7 M $
Pictet Asset Management Holding SA
2.768 %
1,324,246 2.768 % 7 M $
International Biotechnology Trust Plc
2.595 %
1,241,500 2.595 % 6 M $

Company contact information

uniQure NV

Paasheuvelweg 25a

1105 BP, Amsterdam

+31 20 240 6000

http://www.uniqure.com
address uniQure N.V.(QURE)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Ratings for uniQure N.V.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
4.243 EUR
Average target price
18.98 EUR
Spread / Average Target
+347.40%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
UNIQURE N.V. Stock uniQure N.V.
-33.09% 220M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+0.82% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-7.98% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. QURE Stock
  4. Company uniQure N.V.